CYTK CYTOKINETICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, CYTOKINETICS INC reported revenue of $28.6M (down 57.1% from a year earlier), net income of −$199M and diluted EPS of −$1.50; over the last four quarters revenue was $67.7M and net income −$894M; for the fiscal year ended December 2025 revenue was $88.0M, up 376.6% on the year before.

CYTK annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $88.0M, gross profit n/a, operating income −$612M, net income −$785M (margin -891.6%), EPS −$6.54
• Fiscal year ended Dec 2024: revenue $18.5M, gross profit n/a, operating income −$536M, net income −$590M (margin -3191.1%), EPS −$5.26
• Fiscal year ended Dec 2023: revenue $7.53M, gross profit n/a, operating income −$496M, net income −$526M (margin -6988.6%), EPS −$5.45
• Fiscal year ended Dec 2022: revenue $94.6M, gross profit n/a, operating income −$324M, net income −$389M (margin -411.2%), EPS −$4.33
• Fiscal year ended Dec 2021: revenue $70.4M, gross profit n/a, operating income −$186M, net income −$215M (margin -305.7%), EPS −$2.80

CYTK quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $28.6M (down 57.1% year over year), net income −$199M, EPS −$1.50
• Quarter ended Mar 31, 2026: revenue $19.4M (up 1125.8% year over year), net income −$206M, EPS −$1.67
• Quarter ended Dec 31, 2025 (from the annual report): revenue $17.8M (up 4.9% year over year), net income −$183M, EPS −$1.51
• Quarter ended Sep 30, 2025: revenue $1.94M (up 318.1% year over year), net income −$306M, EPS −$2.55
• Quarter ended Jun 30, 2025: revenue $66.8M (up 26714.9% year over year), net income −$134M, EPS −$1.12
• Quarter ended Mar 31, 2025: revenue $1.58M (up 89.1% year over year), net income −$161M, EPS −$1.36
• Quarter ended Dec 31, 2024 (from the annual report): revenue $16.9M (up 912.4% year over year), net income −$150M, EPS −$1.26
• Quarter ended Sep 30, 2024: revenue $463K (up 22.5% year over year), net income −$161M, EPS −$1.36
• Quarter ended Jun 30, 2024: revenue $249K (down 71.3% year over year), net income −$143M, EPS −$1.31
• Quarter ended Mar 31, 2024: revenue $835K (down 81.9% year over year), net income −$136M, EPS −$1.33
• Quarter ended Dec 31, 2023 (from the annual report): revenue $1.67M (down 14.6% year over year), net income −$137M, EPS −$1.38
• Quarter ended Sep 30, 2023: revenue $378K (down 85.0% year over year), net income −$129M, EPS −$1.35
• Quarter ended Jun 30, 2023: revenue $867K (down 99.0% year over year), net income −$129M, EPS −$1.34
• Quarter ended Mar 31, 2023: revenue $4.61M (up 301.8% year over year), net income −$131M, EPS −$1.38
• Quarter ended Dec 31, 2022 (from the annual report): revenue $1.96M (down 96.5% year over year), net income −$137M, EPS −$1.53
• Quarter ended Sep 30, 2022: revenue $2.52M (down 53.7% year over year), net income −$142M, EPS −$1.52
• Quarter ended Jun 30, 2022: revenue $89.0M (up 3029.4% year over year), net income −$19.8M, EPS −$0.23
• Quarter ended Mar 31, 2022: revenue $1.15M (down 82.5% year over year), net income −$89.4M, EPS −$1.05
• Quarter ended Dec 31, 2021 (from the annual report): revenue $55.6M, net income −$30.6M, EPS −$0.33
• Quarter ended Sep 30, 2021: revenue $5.44M, net income −$76.1M, EPS −$0.95

CYTK cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$510M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$396M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$414M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$300M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$143M, share buybacks n/a

CYTK balance sheet

• Jun 30, 2026: cash $255M, total assets $1.92B, total liabilities $2.10B, shareholders' equity −$173M, long-term debt $248M
• Mar 31, 2026: cash $130M, total assets $1.27B, total liabilities $2.10B, shareholders' equity −$827M, long-term debt $247M
• Dec 31, 2025: cash $123M, total assets $1.42B, total liabilities $2.08B, shareholders' equity −$660M, long-term debt $246M
• Sep 30, 2025: cash $225M, total assets $1.44B, total liabilities $1.96B, shareholders' equity −$521M, long-term debt $159M
• Jun 30, 2025: cash $74.9M, total assets $1.23B, total liabilities $1.59B, shareholders' equity −$369M, long-term debt $159M
• Mar 31, 2025: cash $73.7M, total assets $1.26B, total liabilities $1.53B, shareholders' equity −$266M, long-term debt $92.0M
• Dec 31, 2024: cash $94.9M, total assets $1.40B, total liabilities $1.54B, shareholders' equity −$135M, long-term debt $93.2M
• Sep 30, 2024: cash $46.9M, total assets $1.44B, total liabilities $1.45B, shareholders' equity −$13.9M, long-term debt $93.0M

What is CYTK's revenue?

CYTOKINETICS INC reported $67.7M of revenue over its last four quarters, through June 30, 2026.

Is CYTK profitable?

No. CYTOKINETICS INC lost $894M over the last four quarters.

What is CYTK's EPS?

Diluted earnings per share over the last four quarters were −$7.23; −$1.50 in the latest quarter.

CYTK ownership and insider trades · All stocks